{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:57:21Z","timestamp":1792036641216,"version":"4.4.0"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T00:00:00Z","timestamp":1689379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of this open\u2010label, randomized, controlled, in\u2010clinic, 5\u2010parallel\u2010group study was to assess biomarkers of exposure (BoE) to select harmful and potentially harmful constituents in adults who smoke (N = 144) switching to oral tobacco products (on!<jats:sup>\u00ae<\/jats:sup> mint nicotine pouches; test products) compared to continuing smoking cigarettes (CS) and completely quitting all tobacco products (NT). Changes in 20 BoE to select harmful and potentially harmful constituents, including 4\u2010(methylnitrosamino)\u20101\u2010(3\u2010pyridyl)\u20101\u2010butanol (NNAL), were evaluated. Adult smokers smoked their usual brand of cigarettes for 2 days (baseline assessments) and then were randomly assigned to ad libitum use of 2, 4, or 8\u00a0mg test products, CS, or NT for 7\u00a0days. Analysis of covariance was used to assess the Day 7 BoE levels between each group using test products, CS, and NT. The creatinine\u2010adjusted total urinary NNAL and other 18 of 19 BoE levels (except nicotine equivalents [NEs]) were significantly lower (<jats:italic>P<\/jats:italic> &lt; .05) on Day 7, among all test product groups compared to CS. Geometric least\u2010square means were reduced for all biomarkers of exposure, except NEs, in test product groups by approximately 42%\u201396% compared to the CS group, and reductions were comparable to the NT group. The geometric least\u2010square means for urinary NE between the test product and the CS groups, although not significantly different, the Day 7 mean change relative to the CS group were 49.9%, 65.8%, and 101% for the 2, 4, and 8\u00a0mg test product groups, respectively. The substantial reduction in harmful and potentially harmful constituent exposure suggests complete switching from cigarettes to test products may present a harm reduction opportunity for adults who smoke.<\/jats:p>","DOI":"10.1002\/jcph.2293","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T03:40:04Z","timestamp":1686886804000},"page":"1108-1118","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Randomized, Controlled Study to Assess Changes in Biomarkers of Exposures Among Adults Who Smoke That Switch to Oral Nicotine Pouch Products Relative to Continuing Smoking or Stopping All Tobacco Use"],"prefix":"10.1002","volume":"63","author":[{"given":"Jesse","family":"Rensch","sequence":"first","affiliation":[{"name":"Altria Client Services LLC Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Edmiston","sequence":"additional","affiliation":[{"name":"Altria Client Services LLC Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhu","family":"Wang","sequence":"additional","affiliation":[{"name":"Altria Client Services LLC Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Jin","sequence":"additional","affiliation":[{"name":"Altria Client Services LLC Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamadi","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Altria Client Services LLC Richmond VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2014"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69086-7"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6959.901"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622200701679040"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2006.06.028"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1707409"},{"key":"e_1_2_10_8_1","volume-title":"Guidance for Industry. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act, Draft Guidance","author":"FDA","year":"2012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2022.03.019"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2098"},{"key":"e_1_2_10_11_1","unstructured":"WagnerKA DanielsonTL FloraJW et\u00a0al.A comparison of harmful and potentially harmful constituents in on!\u00ae nicotine pouches to harmful and potentially harmful constituents in cigarettes and swedish snus.Paper presented at: the 75th Tobacco Science Research Conference; September 11\u201314 2022;New Orleans LA."},{"key":"e_1_2_10_12_1","volume-title":"Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease","author":"IOM (Institute of Medicine, now called National Academy of Sciences)","year":"2010"},{"key":"e_1_2_10_13_1","article-title":"Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List. Center for Tobacco Products","author":"FDA","year":"2012","journal-title":"Rockville, MD."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntp183"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntp126"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntaa135"},{"key":"e_1_2_10_17_1","unstructured":"FDA.Scientific Review of IQOS Modified Risk Application \u2013 Technical Project Lead Summary Page 12.2020."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-011GC"},{"key":"e_1_2_10_19_1","unstructured":"FDA.Guidance for Industry. Bioanalytical Method Validation. May 2001.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf"},{"key":"e_1_2_10_20_1","volume-title":"Statistical Evaluation of Mutagenicity Test Data","author":"Kirkland D","year":"2008"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/18.5.981"},{"issue":"5","key":"e_1_2_10_22_1","first-page":"927","article-title":"Polycyclic aromatic hydrocarbon metabolites in urine as biomarkers of exposure and effect","volume":"104","author":"Strickland P","year":"1996","journal-title":"Environ Health Perspect"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00065-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2005.05.007"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntab224"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2010.533287"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05948-y"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06172-y"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0948"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040617-013849"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2018.06.010"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/1354750X.2022.2148747"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntu082"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2014.12.016"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.5993\/AJHB.47.3.1"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T05:21:43Z","timestamp":1694323303000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/jcph.2293"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2293","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"assertion":[{"value":"2023-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}